EBMT Global Perspective | Professor Francesca Ferrua: Breakthroughs in Autologous Hematopoietic Stem Cell Gene Therapy for WAS—From Concept to Clinical Practice

EBMT Global Perspective | Professor Francesca Ferrua: Breakthroughs in Autologous Hematopoietic Stem Cell Gene Therapy for WAS—From Concept to Clinical Practice

Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by thrombocytopenia, eczema, and recurrent infections, posing a serious threat to affected children. While allogeneic hematopoietic stem cell transplantation (HSCT) can be curative, it is limited by donor availability, the risk of graft-versus-host disease (GVHD), and conditioning-related toxicity.
EBMT Global Perspective | Professor Annalisa Ruggeri: Cord Blood Transplantation—From Established Platform to Frontier Therapeutic Modality

EBMT Global Perspective | Professor Annalisa Ruggeri: Cord Blood Transplantation—From Established Platform to Frontier Therapeutic Modality

Cord blood transplantation (CBT), an important modality within hematopoietic stem cell transplantation, has faced increasing competition in recent years from alternative donor strategies such as haploidentical transplantation. As a result, the field is undergoing a period of reassessment and transformation. Nevertheless, CBT retains irreplaceable value in selected patient populations, while its potential applications in cell and gene therapy as well as regenerative medicine continue to expand.
Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

As a bellwether for innovation in oncology drug therapy, the evolution of lymphoma treatment reflects the broader trajectory of modernization in Chinese oncology. From the introduction of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in 1992—laying the foundation for chemotherapy—to successive breakthroughs in targeted therapy, immunotherapy, and cellular therapy, China’s lymphoma care has undergone 35 years of transformation, progressing from “following” to “running alongside,” and now to “leading.”
Annual Meeting of the Hematology Branch, CPAM | Professor Yajing Xu: Long-Term Follow-Up Management After Hematopoietic Stem Cell Transplantation—From Digital Solutions to Primary Care Collaboration

Annual Meeting of the Hematology Branch, CPAM | Professor Yajing Xu: Long-Term Follow-Up Management After Hematopoietic Stem Cell Transplantation—From Digital Solutions to Primary Care Collaboration

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Symposium, was held in Changsha. During the meeting, Professor Yajing Xu, Executive Chair and Director of Hematology at Xiangya Hospital, Central South University, was invited by Hematology Frontier to share her insights on the clinical challenges of long-term follow-up after hematopoietic stem cell transplantation (HSCT), standardized management models, and pathways for primary care collaboration. Her discussion aimed to promote the standardization of follow-up systems and improve long-term survival and quality of life for patients.